Clinical Trial Update: A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis [Phase 2]

View source ↗

Summary

The document provides an update that a Phase 2 study of LY4100511 (DC-853) in adults with moderate-to-severe plaque psoriasis has been completed. The sponsor is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• LY4100511 (DC-853) (LY4100511)

Snippet

Sponsor: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | Conditions: Plaque Psoriasis | Phase 2 | Status: COMPLETED